2024
Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for Psychosis
Wannan C, Nelson B, Addington J, Allott K, Anticevic A, Arango C, Baker J, Bearden C, Billah T, Bouix S, Broome M, Buccilli K, Cadenhead K, Calkins M, Cannon T, Cecci G, Chen E, Cho K, Choi J, Clark S, Coleman M, Conus P, Corcoran C, Cornblatt B, Diaz-Caneja C, Dwyer D, Ebdrup B, Ellman L, Fusar-Poli P, Galindo L, Gaspar P, Gerber C, Glenthøj L, Glynn R, Harms M, Horton L, Kahn R, Kambeitz J, Kambeitz-Ilankovic L, Kane J, Kapur T, Keshavan M, Kim S, Koutsouleris N, Kubicki M, Kwon J, Langbein K, Lewandowski K, Light G, Mamah D, Marcy P, Mathalon D, McGorry P, Mittal V, Nordentoft M, Nunez A, Pasternak O, Pearlson G, Perez J, Perkins D, Powers A, Roalf D, Sabb F, Schiffman J, Shah J, Smesny S, Spark J, Stone W, Strauss G, Tamayo Z, Torous J, Upthegrove R, Vangel M, Verma S, Wang J, Rossum I, Wolf D, Wolff P, Wood S, Yung A, Agurto C, Alvarez-Jimenez M, Amminger P, Armando M, Asgari-Targhi A, Cahill J, Carrión R, Castro E, Cetin-Karayumak S, Chakravarty M, Cho Y, Cotter D, D’Alfonso S, Ennis M, Fadnavis S, Fonteneau C, Gao C, Gupta T, Gur R, Gur R, Hamilton H, Hoftman G, Jacobs G, Jarcho J, Ji J, Kohler C, Lalousis P, Lavoie S, Lepage M, Liebenthal E, Mervis J, Murty V, Nicholas S, Ning L, Penzel N, Poldrack R, Polosecki P, Pratt D, Rabin R, Eichi H, Rathi Y, Reichenberg A, Reinen J, Rogers J, Ruiz-Yu B, Scott I, Seitz-Holland J, Srihari V, Srivastava A, Thompson A, Turetsky B, Walsh B, Whitford T, Wigman J, Yao B, Yuen H, Ahmed U, Byun A, Chung Y, Do K, Hendricks L, Huynh K, Jeffries C, Lane E, Langholm C, Lin E, Mantua V, Santorelli G, Ruparel K, Zoupou E, Adasme T, Addamo L, Adery L, Ali M, Auther A, Aversa S, Baek S, Bates K, Bathery A, Bayer J, Beedham R, Bilgrami Z, Birch S, Bonoldi I, Borders O, Borgatti R, Brown L, Bruna A, Carrington H, Castillo-Passi R, Chen J, Cheng N, Ching A, Clifford C, Colton B, Contreras P, Corral S, Damiani S, Done M, Estradé A, Etuka B, Formica M, Furlan R, Geljic M, Germano C, Getachew R, Goncalves M, Haidar A, Hartmann J, Jo A, John O, Kerins S, Kerr M, Kesselring I, Kim H, Kim N, Kinney K, Krcmar M, Kotler E, Lafanechere M, Lee C, Llerena J, Markiewicz C, Matnejl P, Maturana A, Mavambu A, Mayol-Troncoso R, McDonnell A, McGowan A, McLaughlin D, McIlhenny R, McQueen B, Mebrahtu Y, Mensi M, Hui C, Suen Y, Wong S, Morrell N, Omar M, Partridge A, Phassouliotis C, Pichiecchio A, Politi P, Porter C, Provenzani U, Prunier N, Raj J, Ray S, Rayner V, Reyes M, Reynolds K, Rush S, Salinas C, Shetty J, Snowball C, Tod S, Turra-Fariña G, Valle D, Veale S, Whitson S, Wickham A, Youn S, Zamorano F, Zavaglia E, Zinberg J, Woods S, Shenton M. Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for Psychosis. Schizophrenia Bulletin 2024, 50: 496-512. PMID: 38451304, PMCID: PMC11059785, DOI: 10.1093/schbul/sbae011.Peer-Reviewed Original ResearchClinical high-risk individualsClinical high riskNational Institute of Mental HealthInstitute of Mental HealthAttenuated positive symptomsPersistent negative symptomsTransition to psychosisCHR statusHigh riskNegative symptomsPositive symptomsAnxiety symptomsPsychosocial functioningCognitive dataOutcomes of individualsDigital health technologiesDaily surveysPsychosisSCZPublic health needsMental healthNovel pharmacological interventionsSchizophreniaClinical outcomesHealth needs
2023
Aberrant Hierarchical Prediction Errors Are Associated With Transition to Psychosis: A Computational Single-Trial Analysis of the Mismatch Negativity
Hauke D, Charlton C, Schmidt A, Griffiths J, Woods S, Ford J, Srihari V, Roth V, Diaconescu A, Mathalon D. Aberrant Hierarchical Prediction Errors Are Associated With Transition to Psychosis: A Computational Single-Trial Analysis of the Mismatch Negativity. Biological Psychiatry Cognitive Neuroscience And Neuroimaging 2023, 8: 1176-1185. PMID: 37536567, DOI: 10.1016/j.bpsc.2023.07.011.Peer-Reviewed Original ResearchConceptsPrecision-weighted prediction errorsHealthy control participantsCourse of schizophreniaCHR-P individualsLower-level precision-weighted prediction errorsControl participantsLow-level sensoryPredictive coding accountMismatch negativity paradigmHierarchical Gaussian FilterPrediction errorEarly psychosisSingle-trial analysisClinical high riskDouble deviantsMismatch negativityComputational mechanismsElectroencephalography amplitudeFuture psychosisComputational modelSchizophreniaPsychosisIndividualsParticipantsSensor space
2022
Distinct Symptom Network Structure and Shared Central Social Communication Symptomatology in Autism and Schizophrenia: A Bayesian Network Analysis
Han GT, Trevisan DA, Foss-Feig J, Srihari V, McPartland JC. Distinct Symptom Network Structure and Shared Central Social Communication Symptomatology in Autism and Schizophrenia: A Bayesian Network Analysis. Journal Of Autism And Developmental Disorders 2022, 53: 3636-3647. PMID: 35752729, PMCID: PMC10202012, DOI: 10.1007/s10803-022-05620-0.Peer-Reviewed Original ResearchConceptsSchizophrenia spectrum disordersSocial communication difficultiesSymptom networksCognitive-perceptual symptomsSpectrum disorderRepetitive behaviorsNeurodevelopmental conditionsCommunication difficultiesASDPotential treatment targetAutismSymptom network structureDiagnostic groupsTreatment targetsNetwork analysis approachHigh centralitySymptomatologySchizophreniaSymptomsOrganizationAdultsDisordersBayesian network analysisDifficultiesAnalysis approach
2021
Dopamine D1R Receptor Stimulation as a Mechanistic Pro-cognitive Target for Schizophrenia
Abi-Dargham A, Javitch JA, Slifstein M, Anticevic A, Calkins ME, Cho YT, Fonteneau C, Gil R, Girgis R, Gur RE, Gur RC, Grinband J, Kantrowitz J, Kohler C, Krystal J, Murray J, Ranganathan M, Santamauro N, Van Snellenberg J, Tamayo Z, Wolf D, D’Souza D, Srihari V, Gueorguieva R, Patel P, Forselius-Bielen K, Lu J, Butler A, Fram G, Afriyie-Agyemang Y, Selloni A, Cadavid L, Gomez-Luna S, Gupta A, Radhakrishnan R, Rashid A, Aker R, Abrahim P, Nia A, Surti T, Kegeles L, Carlson M, Goldberg T, Gangwisch J, Benedict E, Govil P, Brazis S, Mayer M, de la Garrigue N, Fallon N, Baumvoll T, Abeykoon S, Perlman G, Bobchin K, Elliott M, Schmidt L, Rush S, Port A, Heffernan Z, Laney N, Kantor J, Hohing T, Gray D, Lieberman J. Dopamine D1R Receptor Stimulation as a Mechanistic Pro-cognitive Target for Schizophrenia. Schizophrenia Bulletin 2021, 48: 199-210. PMID: 34423843, PMCID: PMC8781338, DOI: 10.1093/schbul/sbab095.Peer-Reviewed Original ResearchConceptsCortical dopamine neurotransmissionPositive allosteric modulationImportant therapeutic targetPF-06412562Dopaminergic receptorsD1R stimulationDA levelsTolerable dosesLevel of stimulationDopamine neurotransmissionReceptor stimulationTherapeutic targetPartial agonistCognitive deficitsBiased agonismFull agonismTarget engagementAllosteric modulationNew drugsStimulationPoor bioavailabilitySchizophreniaOptimal stimulationDrugsExpression levels
2020
Early Intervention for Schizophrenia: Building Systems of Care for Knowledge Translation
Srihari V, Cahill J. Early Intervention for Schizophrenia: Building Systems of Care for Knowledge Translation. 2020, 191-210. DOI: 10.7551/mitpress/13412.003.0018.Peer-Reviewed Original ResearchEarly interventionMental disordersMental healthLarge disease burdenQuality of lifeKnowledge translationClinical stagingDisease burdenEarly treatmentMental illnessIntervention modalitiesNeural circuitryDiagnostic issuesDisordersInterventionCurrent nosologyBiological mechanismsSchizophreniaOutcomesTreatmentHealthIllnessStagingEpidemiologyH. Chen
2018
Course, outcome and diagnosis stability of early-onset schizophrenia in Yunnan Province, China-a three years follow-up study
Kang C, Zhou H, Yang J, Yang R, Sun N, Wang S, Yang C, Han D, Srihari VH. Course, outcome and diagnosis stability of early-onset schizophrenia in Yunnan Province, China-a three years follow-up study. Psychiatry Research 2018, 271: 144-149. PMID: 30472510, DOI: 10.1016/j.psychres.2018.11.013.Peer-Reviewed Original ResearchConceptsEarly-onset schizophreniaICD-10 diagnosisDiagnostic stabilityMini International Neuropsychiatric InterviewFirst Affiliated HospitalInternational Neuropsychiatric InterviewKunming Medical UniversityHigh diagnostic stabilityDepartment of PsychiatryPoor outcomeAffiliated HospitalNeuropsychiatric InterviewInternational ClassificationBetter outcomesModerate outcomeMedical UniversityGlobal functioningICD-10Psychosocial outcomesPatientsSchizophreniaDiagnosis stabilityDiagnosisOutcomesHospitalTransforming the Treatment of Schizophrenia in the United States: The RAISE Initiative
Dixon LB, Goldman HH, Srihari VH, Kane JM. Transforming the Treatment of Schizophrenia in the United States: The RAISE Initiative. Annual Review Of Clinical Psychology 2018, 14: 1-22. PMID: 29328779, PMCID: PMC8990328, DOI: 10.1146/annurev-clinpsy-050817-084934.Peer-Reviewed Original ResearchConceptsCoordinated Specialty CareInitial Schizophrenia Episode projectExtensive functional impairmentPatient Outcomes Research TeamTreatment of schizophreniaSchizophrenia spectrum disordersEvidence-based practiceUntreated psychosisSpecialty careChronic schizophreniaCSC programsEpisode ProjectFunctional impairmentLifetime prevalenceRAISE studyRecovery of individualsTreatment settingsEarly interventionNeurodevelopmental illnessSchizophreniaTreatmentUnited StatesInternational studiesSpectrum disorderPatients
2017
Searching for Cross-Diagnostic Convergence: Neural Mechanisms Governing Excitation and Inhibition Balance in Schizophrenia and Autism Spectrum Disorders
Foss-Feig JH, Adkinson BD, Ji JL, Yang G, Srihari VH, McPartland JC, Krystal JH, Murray JD, Anticevic A. Searching for Cross-Diagnostic Convergence: Neural Mechanisms Governing Excitation and Inhibition Balance in Schizophrenia and Autism Spectrum Disorders. Biological Psychiatry 2017, 81: 848-861. PMID: 28434615, PMCID: PMC5436134, DOI: 10.1016/j.biopsych.2017.03.005.Peer-Reviewed Original ResearchConceptsAutism spectrum disorderSpectrum disorderFunctional magnetic resonance imagingRecent theoretical accountsEarly course schizophreniaNeurodevelopmental disordersPharmacological challenge studiesNeural correlatesNeuroscience literatureTheoretical accountsNeural circuitryTheoretical neuroscienceNoninvasive neuroimagingBehavioral dysfunctionFuture researchNeuropsychiatric conditionsComputational modelSchizophreniaProton magnetic resonance spectroscopyDisordersInhibition imbalanceMagnetic resonance imagingDistinct modalitiesPoint of convergenceInhibition balance
2015
Equivalent mismatch negativity deficits across deviant types in early illness schizophrenia-spectrum patients
Hay RA, Roach BJ, Srihari VH, Woods SW, Ford JM, Mathalon DH. Equivalent mismatch negativity deficits across deviant types in early illness schizophrenia-spectrum patients. Biological Psychology 2015, 105: 130-137. PMID: 25603283, PMCID: PMC4336819, DOI: 10.1016/j.biopsycho.2015.01.004.Peer-Reviewed Original ResearchConceptsSchizophrenia spectrum patientsHealthy controlsEarly schizophrenia patientsMMN amplitude reductionDuration of illnessCourse of schizophreniaMismatch negativityDeviant typesMismatch negativity deficitsClinical symptomsDifferent deviant typesNeurophysiological abnormalitiesAuditory deviantsSchizophrenia patientsPatientsAuditory deviance processingIllnessNeurophysiological mechanismsAmplitude reductionSignificant interactionMMN responsesDeviance processingSymptomsAbnormalitiesSchizophrenia
2011
Insomnia is frequent in schizophrenia and associated with night eating and obesity
Palmese LB, DeGeorge PC, Ratliff JC, Srihari VH, Wexler BE, Krystal AD, Tek C. Insomnia is frequent in schizophrenia and associated with night eating and obesity. Schizophrenia Research 2011, 133: 238-243. PMID: 21856129, PMCID: PMC5581545, DOI: 10.1016/j.schres.2011.07.030.Peer-Reviewed Original ResearchConceptsBody mass indexQuality of lifeSleep difficultiesMass indexClinical insomniaSevere insomniaNight eatingPoor sleepPsychiatric symptomsTypes of antipsychoticsPrevalence of insomniaRelationship of sleepProminent clinical concernBrief cognitive assessmentIndependent predictorsPoint prevalenceClinical variablesClinical careSleep patternsSchizoaffective disorderClinical concernInsomniaLow qualityWeight gainSchizophrenia
2008
Atypical antipsychotics for people with both schizophrenia and depression
Furtado V, Srihari V, Kumar A. Atypical antipsychotics for people with both schizophrenia and depression. 2008, 2012: cd005377. PMID: 18254078, PMCID: PMC4171386, DOI: 10.1002/14651858.cd005377.pub2.Peer-Reviewed Original ResearchConceptsAtypical antipsychotic drugsAntipsychotic drugsGroup RegisterRelative riskCochrane Schizophrenia Group's RegisterNew atypical antipsychotic drugHomogenous dichotomous dataRelevant pharmaceutical companiesCo-morbid depressionConfidence intervalsTreatment of peopleLower depression scoresHaloperidol comparisonsTreat basisRandomised trialsAtypical antipsychoticsDATA COLLECTIONClinical trialsHamilton scorePANSS scoresDepression scoresDichotomous dataMean differenceMore trialsSchizophrenia